K. Sean Kimbro is a professor of Biological and Biomedical Sciences at the North Carolina Central University, Durham, NC. He also serves as the principal investigator for the Center for Translational Health Equality Research, a center created to provide infrastructure for the study of various health disparities in North Carolina, with an emphasis on cardiovascular metabolic disparities.
Dr. Kimbro received his undergraduate from Washington University in St. Louis, Missouri, and his PhD in Molecular and Microbiology from Indiana University, Bloomington, Indiana. From 1993 to April 1995, he was a postdoctoral fellow at Harvard Medical School and from 1995 to 1997 a fellow at the National Institutes of Health, National Institute of Environmental Health Sciences.
Dr. Kimbro was later an assistant professor at Clark Atlanta University, Department of Biological Sciences, in Atlanta, Georgia. In 2004, Dr. Kimbro was recruited to direct the NIH Center of Excellence at Winship Cancer Institute, which he helped conceive. He was later recruited to North Carolina Central University to be the director of the Julius L. Chambers Biomedical/Biotechnology Research Institute in 2010. In 2014, Dr. Kimbro received funding to continue his research in cancer health disparities and returned to the lab to study immunity and breast/prostate cancers, including type 2 diabetes and obesity.
Dr. Kimbro's research interests include the molecular characterization of hormonal cancers, including prostate and breast cancer. He has additional interests in the characterization of those cancers that disproportionately affect various ethnic groups. More recently, he has ventured into epigenetic research exploring the role of microRNAs in type 2 diabetes of African Americans. He has been influential in the continued efforts to increase the number of African-American and Hispanic American cancer researchers and the recipient of numerous awards from the American Association for Cancer Research. In addition to his success in the classroom, mentoring, and leadership, he has generated over 10 million dollars in research over his career.
Indiana University, Bloomington
Washington University in St. Louis
1. Hooker, S. E., & Williams-Burnham, L., & Kimbro, K. S., & Kittles, R. (2019). Genetic ancestry analysis reveals misclassification of commonly used cancer cell lines. Cancer Epidemiol Biomarkers Prev.
2. Dubey, B. M., & Jackson, M. D., & Zeigler-Johnson, C., & Devarajan, K. (2017). Inflammation polymorphisms and prostate cancer risk in Jamaican men: Role of obesity/body size. Gene, 636, 96-102.
3. Z, J. D., & C, R., & C, K. N., & B, B. G. (2013). The impact of genetic variants in inflammatory-related genes on prostate cancer risk among men of African Descent: a case control study. Hered Cancer Clin Pract., 11, 19.
4. Yeyeodu, S. T., & Kidd, L. R., & Oprea-Llies, G. M. (2013). IRAK4 and TLR3 Sequence Variants may Alter Breast Cancer Risk among African-American Women. Frontiers in Immunity, 4, 338.
5. N, R. E., & Z, J. D., & C, K. N., & G, B. (2013). Toll-like receptor-associated sequence variants and prostate cancer risk among men of African descent. Genes Immun., 14, 347-355.
6. Kidd, L. R., & Jones, D. Z., & Rogers, E. N., & Kidd, N. C. (2012). Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent: a case-control study. Hered Cancer Clin Pract., 10, 16.
7. Lavender, N. A., & Rogers, E., & Yeyeodu, S., & Rudd, J. (2012). Interaction among apoptosis-associated sequence variants and joint effects on aggressive prostate cancer. BMC Med Genomics, 5.